Drug Trial Radar · NCT07266441
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
168
Actual
Start
Feb 8, 2026
Primary completion
Jun 14, 2027
Study completion Dec 12, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Conditions
- Multiple Myeloma
Interventions
JNJ-79635322Drug
JNJ-79635322 will be administered as an injection under the skin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Up to 2 years and 9 months
Locations
71 sites in 8 countries. Site status is shown where the registry gives one.
O Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama
Banner MD Anderson Cancer Center
Gilbert, Arizona
City of Hope
Duarte, California
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
University of California San Francisco
San Francisco, California
Rocky Mountain Cancer Centers
Aurora, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
Cancer Specialists of North Florida
Jacksonville, Florida
Emory University
Atlanta, Georgia
Northside Hospital Cancer Institute
Atlanta, Georgia
Cancer Care Specialists of Central Illinois
O'Fallon, Illinois
University of Iowa
Iowa City, Iowa
Mission Cancer Blood
Waukee, Iowa
Massachusetts General Hospital
Boston, Massachusetts
Rutgers Cancer Institute
New Brunswick, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Cleveland Clinic Foundtation
Cleveland, Ohio
Oncology Associates of Oregon PC Willamette Valley Cancer Institute
Eugene, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
SCRI Oncology Partners
Nashville, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Texas Oncology
Austin, Texas
MD Anderson Cancer Center
Houston, Texas
Oncology Consultants Texas
Houston, Texas
Texas Oncology - Northeast
Tyler, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
NorthWest Medical Specialties, PLLC
Tacoma, Washington
Peking Union Medical College Hospital
Beijing, China
Beijing Chaoyang Hospital
Chaoyang District, China
Sun Yat Sen University Cancer Center
Guangzhou, China
Shanghai Fourth People s Hospital
Shanghai, China
Ha'Emek Medical Center
Afula, Israel
Samson Assuta Ashdod University Hospital
Ashdod, Israel
Hillel Yaffe Medical Center
Hadera, Israel
Hadassah Medical Center
Jerusalem, Israel
Rabin Medical Center
Petah Tikva, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.